Rifaximin: New Therapeutic Indication and Future Directions

Clinical Therapeutics

Volumn 33, Issue 7, 2011, Pages 812-827

  Rivkin, Anastasia ^a   Gim, Suzanna ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Clostridium difficile; Irritable bowel syndrome; Recurrent hepatic encephalopathy; Rifaximin

Indexed keywords

ETHINYLESTRADIOL; LACTITOL; LACTULOSE; METRONIDAZOLE; MIDAZOLAM; NEOMYCIN; NORGESTIMATE; PAROMOMYCIN; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASCITES; BREAST CANCER; CHOLECYSTITIS; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDICATION; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INTESTINE FLORA; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; RECURRENT DISEASE; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TASTE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 79960207685     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.06.007     Document Type: Review

References (70)

1. Scarpignato C., Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006, 73:13-27.
2. Descombe J.J., Dubourg D., Picard M., Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994, 16:51-56.
3. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071.
4. Xifaxan (rifaximin) tablets [package insert] 2010, Salix Pharmaceuticals, Morrisville, NC.
5. NDA approval letter # 022554 Updated 2010. Accessed November 2, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010.
6. Ripa S., Mingini F., Prenna M., Falcioni E. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campilobacter jejunii and Yersinia spp. Drugs Exp Clin Res 1987, 13:483-488.
7. Megraud F., Bouffant F., Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994, 13:184-186.
8. Amenta M., Dalle Nogare E.R., Colomba C., et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother 1999, 11:391-395.
9. Gillis J.C., Brogden R.N. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995, 49:67-84.
10. Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity-a review. Chemotherapy 2005, 51:67-72.
11. Jiang Z.D., Ke S., Palazzini E., et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000, 44:2205-2206.
12. al-Orainey I.O. Drug resistance in tuberculosis. J Chemother 1990, 2:147-151.
13. Spratt B.G. Resistance to antibiotics mediated by target alterations. Science 1994, 264:388-393.
14. Marchese A., Salerno A., Pesce A., et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000, 46:253-266.
15. Hoover W.W., Gerlach E.H., Hoban D.J., et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993, 16:111-118.
16. DuPont H.L., Jiang Z.D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Inf 2004, 10:1009-1011.
17. De Leo C., Eftimiadi C., Schito G.C. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986, 12:979-981.
18. Testa R., Eftimiadi C., Sukkar G.S., et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985, 11:387-392.
19. Briefing document for gastrointestinal drug advisory committee meeting of the FDA Accessed February 11, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf.
20. Trapnell C.B., Connolly M., Pentikis H., et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007, 41:222-228.
21. Pentikis H.S., Connolly M., Trapnell C.B., et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007, 27:1361-1369.
22. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):3-9.
23. Ryan L. Portal hypertension and cirrhosis. Pharmacotherapy Principles and Practice 2010, 387-402. McGraw-Hill Medical, New York, NY. 2nd ed. M.A. Chisholm-Burns, T.L. Schwinghammer, B.G. Wells (Eds.).
24. Ferenci P. Hepatic encephalopathy. Bockus Gastroenterology 1995, 1998-2003. WB Saunders, Philadelphia, Pa. 5th ed. W.S. Haubrich, F. Schaffner, D.K. Bettenhausen (Eds.).
25. Bustamante J., Rimola A., Ventura P.J., et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999, 30:890-895.
26. Al Sibae M.R., McGuire B.M. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag 2009, 5:617-626.
27. Stewart C.A., Malinchoc M., Kim W., Kamath P.S. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007, 13:1366-1371.
28. Ahboucha S., Butterworth R.F. Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis 2004, 19:331-343.
29. Blei A.T., Córdoba J. Hepatic encephalopathy. Am J Gastroenterol 2001, 96:1968-1976.
30. Bajaj J.S. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010, 31:537-547.
31. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive function and health-related quality of life in cirrhotic patients with minimal hepatic encephalopathy. Hepatology 2007, 45:549-559.
32. Sharma P., Sharma B.C., Puri V., Sarin S.K. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008, 20:506-511.
33. Sharma B.C., Sharma P., Agrawal A., Sarin S.K. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009, 137:885-891.
34. Zeneroli M.L., Avallone R., Corsi L., et al. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 2005, 51:90-95.
35. Leevy C.B., Phillips J.A. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007, 52:737-741.
36. Wolf D.C. Encephalopathy, Hepatic Medscape Reference, Accessed November 1, 2010. http://emedicine.medscape.com/article/186101-overview.
37. List of Orphan Products Designations and Approvals US Food and Drug Administration, Updated 1999. Accessed October 29, 2010. http://www.fda.gov/ohrms/dockets/dailys/00/mar00/030100/lst0094.pdf.
38. Lawrence K.R., Klee J.A. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008, 28:1019-1032.
39. Maclayton D.O., Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009, 43:77-84.
40. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977, 72:573-583.
41. Brown R.S., Kumar K.S., Russo M.W., et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002, 8:278-284.
42. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. Am J Gastroenterol 2009, 104:S1-S35.
43. Lembo A., Zakko S.F., Ferreira N.L., et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008, 134(Suppl 1):A-545.
44. Pimentel M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006, 145:557-563.
45. Sharara A.I., Aoun E., Abdul-Baki H., et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326-333.
46. Yang J., Lee H.R., Low K., et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008, 53:169-174.
47. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
48. Pimentel M., Lembo A., Chey W.D., et al. Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American Phase 3 trials (Target 1 and Target 2). Gastroenterology 2010, 138:475i.
49. Pimentel M., Lembo A., Chey W.D., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011, 364:22-32.
50. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
51. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992, 15:573-581.
52. Bartlett J.G. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984, 6:235-241.
53. Olson M.M., Shanholtzer C.J., Lee J.T., Gerding D.N. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994, 15:371-381.
54. Johnson S., Adelmann A., Clabots C.R., et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989, 159:340-343.
55. Barbut F., Richard A., Hamadi K., et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000, 38:2386-2388.
56. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
57. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
58. Hecht D.W., Galang M.A., Sambol S.P., et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007, 51:2716-2719.
59. Garey K.W., Jiang Z.D., Bellard A., Dupont H.L. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009, 43:91-93.
60. Basu P.P., Dinani A., Rayapudi K., et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Ther Adv Gastroenterol 2010, 3:221-225.
61. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44:846-848.
62. Johnson S., Schriever C., Patel U., et al. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15:290-291.
63. Neff G., Zacharias V., Kaiser T.E., et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl 2010, 16:960-963.
64. Berman A.L. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2007, 41:932-933.
65. O'Connor J.R., Galang M.A., Sambol S.P., et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008, 52:2813-2817.
66. Curry S.R., Marsh J.W., Shutt K.A., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48:425-429.
67. Mullen K., Sigal S., Sheikh M. Safety of rifaximin in patients with hepatic encephalopathy: results of a randomized, phase 3, placebo-controlled clinical trial. J Hepatol 2009, 50(Suppl 1):S84-S85.
68. Neff G.W., Kemmer N., Zacharias V.C., et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006, 38:3552-3555.
69. Kinray, Inc., Updated 2010. Accessed October 25, 2010. http://www.kinray.com.
70. ClinicalTrials.gov: a service of the US National Institutes of Health, Updated 2010. Accessed November 2, 2010. http://www.clinicaltrials.gov.